Aktuellt
SENASTE
Redeye is encouraged by the strong sales development, boosted by Catalyst contributing to c60% of US sales. While its spine product certainly positively surprised us, we emphasise a continuously challenging climate for elective surgeries and restricted hospital access, likely to depress sales in the medium term. We adjust our fair value range downwards following the report.
LÄS MER
